Results 181 to 190 of about 64,429 (258)

Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions. [PDF]

J Clin Med
Katsi V, Nikolopoulou L, Fragoulis C, Kordalis V, Tsioufis K, Toutouzas K.   +5 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Correction: Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists. [PDF]

Cardiovasc Toxicol
Khatami S, Faghihi M, Tavakoli G, Szmit S, Yousefifard M.   +4 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity. [PDF]

Dose Response
Guan Y, Mei J, He Y, Lu M, Cheng B, Zhang X.   +5 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Cardiotoxicity of newer HER2-Directed therapies in breast cancer: A systematic review and meta-analysis of incidence and comparative risk. [PDF]

Breast
Sundaramoorthy S, Gokulanathan N, Joseph P R, Tm A, Mathew SP, Kaur H, Muthukumarasamy T, Jose J, Jayaraman KB, Rajmohan P, Thovarayi V, Sathyadas A, Ignatious SV, Valaparambil SA.   +13 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Significance of Cardiac Troponin in Cancer Patients. [PDF]

Cells
Birgés K, Merkely B, Molnár AÁ.
europepmc   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann, Zsanett Papdi, Nils J. Strauch, Daniel Finke, Marc‐Steffen Raab, Antje Blank, Norbert Frey, Lorenz H. Lehmann   +7 more
wiley   +1 more source